166 related articles for article (PubMed ID: 28057420)
1. Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.
Singh K; Tanui R; Gameiro A; Eisenberg G; Colas C; Schlessinger A; Grewer C
Bioorg Med Chem Lett; 2017 Feb; 27(3):398-402. PubMed ID: 28057420
[TBL] [Abstract][Full Text] [Related]
2. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
3. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.
Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC
Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak.
Grewer C; Grabsch E
J Physiol; 2004 Jun; 557(Pt 3):747-59. PubMed ID: 15107471
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the neutral amino acid transporter ASCT2 with basic amino acids.
Ndaru E; Garibsingh RA; Zielewicz L; Schlessinger A; Grewer C
Biochem J; 2020 Apr; 477(8):1443-1457. PubMed ID: 32242892
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity.
Oppedisano F; Catto M; Koutentis PA; Nicolotti O; Pochini L; Koyioni M; Introcaso A; Michaelidou SS; Carotti A; Indiveri C
Toxicol Appl Pharmacol; 2012 Nov; 265(1):93-102. PubMed ID: 23010140
[TBL] [Abstract][Full Text] [Related]
7. Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) Ligands with Novel Serine Analogs.
Albers T; Marsiglia W; Thomas T; Gameiro A; Grewer C
Mol Pharmacol; 2012 Mar; 81(3):356-65. PubMed ID: 22113081
[TBL] [Abstract][Full Text] [Related]
8. Rational design of ASCT2 inhibitors using an integrated experimental-computational approach.
Garibsingh RA; Ndaru E; Garaeva AA; Shi Y; Zielewicz L; Zakrepine P; Bonomi M; Slotboom DJ; Paulino C; Grewer C; Schlessinger A
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507995
[TBL] [Abstract][Full Text] [Related]
9. 2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency.
Schulte ML; Dawson ES; Saleh SA; Cuthbertson ML; Manning HC
Bioorg Med Chem Lett; 2015 Jan; 25(1):113-6. PubMed ID: 25435145
[TBL] [Abstract][Full Text] [Related]
10. Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site.
Esslinger CS; Cybulski KA; Rhoderick JF
Bioorg Med Chem; 2005 Feb; 13(4):1111-8. PubMed ID: 15670919
[TBL] [Abstract][Full Text] [Related]
11. Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.
Scopelliti AJ; Font J; Vandenberg RJ; Boudker O; Ryan RM
Nat Commun; 2018 Jan; 9(1):38. PubMed ID: 29295993
[TBL] [Abstract][Full Text] [Related]
12. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
14. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.
Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A
PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Synthesis of Hydroxy-l-Proline Blockers of the Neutral Amino Acid Transporters SLC1A4 (ASCT1) and SLC1A5 (ASCT2).
Lyda BR; Leary GP; Farnsworth J; Seaver B; Silvius D; Kavanaugh MP; Esslinger CS; Natale NR
Molecules; 2024 May; 29(10):. PubMed ID: 38792190
[TBL] [Abstract][Full Text] [Related]
16. Cryo-EM structure of the human neutral amino acid transporter ASCT2.
Garaeva AA; Oostergetel GT; Gati C; Guskov A; Paulino C; Slotboom DJ
Nat Struct Mol Biol; 2018 Jun; 25(6):515-521. PubMed ID: 29872227
[TBL] [Abstract][Full Text] [Related]
17. Inactivation by Hg2+ and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes: Prediction of the involvement of a CXXC motif by homology modelling.
Oppedisano F; Galluccio M; Indiveri C
Biochem Pharmacol; 2010 Oct; 80(8):1266-73. PubMed ID: 20599776
[TBL] [Abstract][Full Text] [Related]
18. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
19. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.
Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W
Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035
[TBL] [Abstract][Full Text] [Related]
20. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
